Lipoprotein(a) (Lp(a)), the protein product of the LPA gene, is a plasma lipoprotein particle with multiple biological functions. The apo(a) component possesses serine proteinase activity and inhibits tissue-type plasminogen activator, potentially modulating fibrinolysis. However, the provided abstracts primarily address lysophosphatidic acid (LPA), a distinct bioactive phospholipid unrelated to the Lp(a) protein. Regarding Lp(a) protein: Elevated Lp(a) concentrations represent a significant cardiovascular risk factor. Concentrations >50 mg/dL increase calcific aortic valve disease (CAVD) risk 1.95-fold 1. High LPA gene expression promotes endothelial-to-mesenchymal transition in aortic valve endothelial cells through TGF-Ξ² signaling and oxidative stress pathways, contributing to aortic valve calcification 1. Clinically, Lp(a) levels are emerging as an independent cardiovascular risk marker, distinct from traditional lipid parameters. The association between LPA genetic variants and CAVD suggests potential therapeutic targeting of Lp(a)-mediated pathways for cardiovascular disease prevention 1. Note: The abstracts provided contain limited information about Lp(a) protein function. Most retrieved abstracts address lysophosphatidic acid signaling through G-protein coupled receptors, which is mechanistically distinct from Lp(a) lipoprotein particle biology.